This content is from the "Advancing the Science of Cancer in Latinos: 2024 Conference Proceedings."
Non-Medical Drivers of Health Impacting Latino Cancer Health Gaps: Genetic Cancer Risk Assessment
Dr. Alejandra Hurtado de Mendoza is an Assistant Professor at the Cancer Prevention and Control Program at Georgetown Lombardi Comprehensive Cancer Center. Gaps across the continuum Dr. Hurtado de Mendoza’s presentation focused on gaps in genetic cancer risk assessment, multi-level hurdles that Latinos face across the genetic cancer risk assessment continuum, and an example of a multilevel intervention to decrease gaps. The presentation began by discussing how gaps in the genetic cancer risk assessment continuum begin with awareness. Only 23% of Latino individuals were aware of ...
This content is from the "Advancing the Science of Cancer in Latinos: 2024 Conference Proceedings."
Latino Cancer Survivors’ Quality of Life and Survivorship Care
Dr. Kristi D. Graves is a tenured Professor of Oncology, Cancer Prevention and Control Program leader at the Lombardi Comprehensive Cancer Center, and Associate Dean for Faculty Development at Georgetown University Medical Center. Latino cancer survivorship Dr. Graves’s presentation began by discussing cancer survivorship across the cancer continuum. The National Cancer Institute’s (NCI) Office of Cancer Survivorship states that “an individual is considered a cancer survivor from the time of diagnosis through the balance of life. There are many types of survivors, including those living with cancer and those ...
This content is from the "Advancing the Science of Cancer in Latinos: 2024 Conference Proceedings."
Adapting NCI’s Clinical Trials System to a Changed Clinical Research Environment
Dr. James H. Doroshow is Deputy Director for Clinical and Translational Research at the National Cancer Institute (NCI). This plenary session occurred at 8:30 am., Thursday, Feb. 22, 2024, at the 4th biennial Advancing the Science of Cancer in Latinos conference. COVID’s impact on cancer clinical trials Dr. Doroshow’s presentation began by discussing the initial and continuing effects of the pandemic environment on cancer clinical trials. From the start of the pandemic, several aspects of clinical trials were altered, including informed consent and in-person study activities. One major ...
This content is from the "Advancing the Science of Cancer in Latinos: 2024 Conference Proceedings."
Advances in Evidence-based Digital Solutions for Supporting Latino Cancer Patients
Dr. John Piette is Professor in the School of Public Health, and Director of the Center for Managing Chronic Disease (CMCD) at the University of Michigan. Cognitive behavioral therapy Dr. Piette’s presentation began by discussing how cognitive behavioral therapy (CBT) can be used for Latino cancer patients. CBT is the most common evidence-based intervention for cancer patients struggling with mental health, symptoms, stress, and sleep. In cancer patients, CBT has been shown to help manage distress and pain, alleviate insomnia, manage fear of cancer recurrence, and reduce emotional distress and ...
This content is from the "Advancing the Science of Cancer in Latinos: 2024 Conference Proceedings."
The NCI Community Oncology Research Program: Opportunities to Increase Latino Participation in Clinical Trials
Dr. Brenda Adjei is Associate Director of the HDRP at the National Cancer Institute (NCI) Center for Cancer Research. The NCI Community Oncology Research Program Dr. Adjei’s presentation began with a discussion of Latino participation in cancer clinical trials. Variety in clinical trials is critically important because it generates biomedical knowledge relevant to all, builds trust and trustworthiness, and contributes to reductions in health gaps and fair research participation. Current limits in clinical research is due to multilevel hurdles and requires tailored, ...
This content is from the "Advancing the Science of Cancer in Latinos: 2024 Conference Proceedings."
Conclusion
To eliminate gaps in cancer care in Latino populations, Advancing the Science of Cancer in Latinos brought together researchers, scientists, physicians, healthcare professionals, patient navigators, and students from across the US and Latin America. These presenters shared research advancements, identified gaps, developed actionable goals, updated clinical best practices, described effective community interventions, and detailed professional training programs aimed at addressing inequity. In the process, most of the speakers made recommendations, either specific to their field of study or more broadly. The following are some key recommendations abstracted from their conference ...
This content is from the "Advancing the Science of Cancer in Latinos: 2024 Conference Proceedings."
Healthcare Gaps in the Latino Community
The Latino population both within and outside the US has significant heterogeneity. [Velazquez-Villarreal] After all, Latin America has been a melting pot of mixed populations for 500 years, with over 20 heritage groups recognized by the Hispanic Community Health Study/Study of Latinos. These groups are distinct, with unique backgrounds, language, and US influence, but are also connected by more similarities than differences. [Perez-Stable] Latino individuals are the largest and youngest overlooked community in the US and are projected to account for more than half of the overall growth through 2060. Compared to non-Hispanic White individuals, ...
More than 2 million people in the United States are expected to be diagnosed with cancer this year. No two among them will experience cancer exactly the same way. Even so, certain groups of people will share similar cancer experiences. Latinos face higher rates of cervical, liver, and stomach cancers. Black women with ovarian cancer don’t live as long as White women with the disease. People living in rural areas are less likely to get regular cancer screenings than those who live in cities. And people who live in areas where poverty has been the norm for decades are more likely to die of cancer than those living in more affluent areas. These patterns of worse outcomes among specific groups of people are called cancer differences. Although biological differences can contribute to ...
Dr. Patricia Chalela, a researcher at the Institute for Health Promotion Research (IHPR) at UT Health San Antonio, has been named the IBC Foundation Endowed Professorship in Health Promotion Research. The International Bancshares Corporation (IBC) Foundation is a private foundation affiliated with IBC and its subsidiary banks. It is dedicated to supporting charities that enrich the community and improve the health and wellness of people in Texas and Oklahoma. The foundation made a $2 million donation that established four endowed professorships at UT Health San Antonio. Dr. Chalela's endowment, which is for $500,000, aims to help her advance novel research in health promotion. "I am deeply honored and sincerely grateful to be nominated as the recipient of the IBC Foundation ...
